Editas Medicine Культура компании

Ms. Katrine S. Bosley has been the Chief Executive Officer and President of Editas Medicine Inc. since June 24, 2014. Ms. Bosley served as the Chief Executive Officer at Celgene Avilomics Research, Inc. She served as Vice President of Business Development at Adnexus Therapeutics Inc. She served as Vice President of Strategic Operations at Adnexus Therapeutics Inc. since August 2004. She has been a leader in emerging companies with broad platforms for innovative medicines. She has over 20 years experience in the biotechnology industry in the U.S. and in Europe. Prior to joining Compound Therapeutics Inc. in September 20, 2004, she spent more than eight years with Biogen Idec, Inc. in a variety of corporate and business development roles and served as its Director of Decision Support from 1995 to 2004. She managed commercial analysis for Avonex and Amevive, including market research, sales forecasting and other analytical functions. At Biogen Idec, she had roles in business development, commercial operations and portfolio strategy in the U.S. and Europe. From 1993 to 1995, Ms. Bosley served as Analyst for Highland Capital Partners, a venture capital firm. During her tenure at Biogen Idec, she completed a number of business transactions and she led the deal between Biogen and Elan Pharmaceuticals for Antegren (natalizumab). She contributed to collaborations with Merck, Inhale Therapeutic Systems (Nektar), NsGene, Ontogeny (Curis) and others spending part of her time based out of Biogen's European headquarters in Paris. She led the corporate long-range plan and portfolio prioritization processes, conducted market research and developed product positioning for early stage products and served as Manager of Investor Relations. Ms. Bosley was part of the healthcare team at Highland Capital Partners, where she evaluated investment opportunities in biotechnology, medical device and healthcare service companies. She has been Chairman of Genocea Biosciences, inc. since August 2013. she was also in regulatory affairs at Alkermes, Inc. and coordinated the filing of their first IND. She has been an Independent Non-Executive Director at Galapagos NV since March 4, 2013. She has been Director at Editas Medicine Inc. since June 2014. She serves as a Director of Coco Therapeutics. She has been an Independent Director of Genocea Biosciences, Inc., since March 2013. She serves as a Director of Avila Therapeutics, Inc. She served as a Director of Scholar Rock, Inc. until May 25, 2017. She is the Entrepreneur-in-Residence at The Broad Institute. Ms. Bosley graduated with a B.A. in Biology from Cornell University and completed the Program for Management Development at Harvard Business School.

Dr. Gerald Cox, M.D., Ph.D., has been Chief Medical Officer of Editas Medicine Inc. since October 3, 2016. Dr. Cox is one of the leading clinicians in the industry of developing innovative medicines for genetic diseases, having brought multiple products through development to approval. Dr. Cox held senior clinical development roles at Sanofi Genzyme (formerly, Genzyme Corporation) for over 15 years, most recently as Vice President of Rare Disease Clinical Development. He was instrumental in the development and approval of treatments for lysosomal storage disorders, including the enzyme replacement therapies Aldurazyme??? (iduronidase) for Mucopolysaccharidosis type I in 2003, Myozyme??? (alglucosidase alfa) for Pompe disease in 2006 and Elaprase??? (idursulfase) for Mucopolysaccharidosis type II in Japan and the Asia Pacific region in 2007 and the substrate reduction therapy Cerdelga??? (eliglustat) for Gaucher disease type 1 in 2014. He has spent more than 20 years as a practicing clinical geneticist at Boston Children's Hospital. He serves as part-time in his role as Staff Physician in Genetics at Boston Children's Hospital, where he previously completed an internship and residency in pediatrics followed by clinical and post-doctoral research fellowships in genetics and was Director of the Medical Genomics Mapping Facility. Dr. Cox is also an Instructor in Pediatrics at Harvard Medical School. Dr. Cox received his M.D. and Ph.D. from the University of California at San Diego and his B.A. from Harvard College.

Dr. George M. Church, Ph.D., serves as a Scientific Advisor of Axcella Health, Inc. (alternative name Pronutria, Inc.). Dr. Church is the Founder and Member of Scientific Advisory Board at AbVitro LLC. He is the Co-Founder of Egenesis Inc. He is the Co-Founder, SAB Chairman and Inventor of READCOOR, INC. Dr. Church co-founded REG Life Sciences, LLC in 2005. He co-founded Editas Medicine Inc. in 2013 and serves its Scientific Advisory Board Member. Dr. Church serves as an Advisor of Noblegen Biosciences, Inc., GnuBIO, Inc. and Rose Ventures, Inc. He co-founded enEvolv, Inc. in 2011 and serves as its Chief Science Advisor. He is the Co-Founder at Gen9, Inc. Dr. Church serves as a Technical Advisor at Joule Unlimited, Inc. (formerly, Joule Biotechnologies Inc). He co-founded LS9 Inc. in 2005. He has been directing one of the first funded genome technology centers (Now a DOE GTL systems biology center) focused on photosynthesis and biofuels since 1987. He serves as a Senior Editor of Nature-EMBO Molecular Systems Biology. He co-founded Whitehead genome center (Now the Broad Institute of Harvard & MIT). He served as Advisor of 23andMe, Inc. He serves as a Director of the U.S. Department of Energy Center on Bioenergy at Harvard and MIT, Director of the National Institutes of Health Center of Excellence in Genomic Science at Harvard, MIT and Washington University. He serves as a Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and MIT. Dr. Church served in advisory roles for 12 journals, 5 granting agencies and 22 biotech companies. He co-founded Knome Inc. in 2007 and served as its Chief Scientific Advisor. He served as a Medical Advisor of DNA Direct, Inc. He Co-Founded Codon Devices, Inc. in 2004 and served as its Chief Scientific Officer (CSO). He was the Founder or advisor of more than 20 life sciences companies. He advised 24 companies, including founding JouleBio. His research focused on integrating bio-systems modeling with high-throughput data for haplotypes, RNA arrays, proteomics and metabolites and helped initiate the Human Genome Project in 1984. He helped to found the Stanford, MIT and Waltham Genome Centers. He was a Research Scientist at newly-formed Biogen Inc. and a Monsanto Life Sciences Research Fellow at UCSF. He co-Founded Veritas Genetics International Ltd. in 2014 and serves as its Chairman of Medical & Scientific Advisory Board. He serves as the Chairman of Scientific Advisory Board at Enzymatics Inc., Joule and Knome Inc. He served as the Chairman and Member of the Scientific Advisory Board at Codon Devices, Inc. He serves as a Member of Scientific Advisory Board at Seres Therapeutics, Inc. He serves as Member of Scientific Advisory Board at Recombinetics, Inc. He serves as Member of the Scientific Advisory Board at BioViva USA Inc. He serves as a Director of the Lipper Center for Computational Genetics. He serves as a Director of the Personal Genome Project, as well as Member of the Wyss Institute and Broad Institute. He is a founding core faculty member at the Wyss Institute. He serves as a Director of NIH Center for Excellence in Genome Science. He serves as a Director of PersonalGenomes.org the world's only open-access information on human Genomic, Environmental & Trait data (GET). He serves as a Member of Advisory Board at Two Pore Guys, Inc. He has been an Independent Director of Sigma-Aldrich Corporation since October 2009. Dr. Church was a Member of Scientific Advisory Board at Pathway Genomics Corporation since February 27, 2014. He has been a Member of Scientific Advisory Board at Genomatica, Inc. since July 2004, AOBiome, LLC since May 2014 and Cellular Dynamics International, Inc. (known as iPS Cells Inc.) since August 2009. He serves as a Member of Scientific Advisory Board at Parabase Genomics, Inc., Complete Genomics, Inc., Intelligent Bio-Systems, Inc. Genia Technologies, Inc. (alternate name, Genia Corporation) and GenapSys, Inc. He serves as a Member of the Advisory Board at BGI Tech Solutions Co., Ltd. He serves as a Director of Sigma-Aldrich Company Limited. He serves as a Member of Scientific Advisory Board and Director at Gen9, Inc. He serves as a Member of the Advisory Board for Caliper Technologies, Genome Pharmaceuticals, Beyond-Genomics and various scientific journals. He serves as a Member of Scientific Advisory Board at 23andMe, Inc. He has been a Member of Advisory Board at Solve, Inc. since June 23, 2016. He serves as a Member of the Board of Advisors at Halcyon Molecular, Inc. He serves as director of the Harvard NHGRI Center of Excellence in Genomic Science. He serves as a Member of Scientific Advisory Board at Ion Torrent Systems Incorporated. He served as a Member of Scientific Advisory Board of LS9, Inc. He served as a Member of Scientific Advisory Board at Helicos Biosciences Corporation. He served as a Member of Scientific Advisory Board at REG Life Sciences, LLC. He served as a Member of Scientific Advisory Board at Receptor BioLogix, Inc. His honors include election to NAS & NAE and Franklin Bower Laureate for Achievement in Science. His innovations in ???next generation??? genome sequencing and synthesis & cell/tissue engineering resulted in 12 companies spanning fields including medical genomics (Knome, Alacris, AbVitro, GoodStart, Pathogenica) and synthetic biology (LS9, Joule, Gen9, Warp Drive) as well as new privacy, biosafety & biosecurity policies. He invented the broadly applied concepts of molecular multiplexing and tags, homologous recombination methods, array DNA synthesizers and multiplex automated genome engineering (MAGE). He began research at Duke University, where he co-authored research on 3D-structural software and RNA with Sung-Hou Kim. He developed the first direct genomic sequencing method with Walter Gilbert in 1984. He is the author of 9 issued U.S. patents and over 100 peer reviewed scientific articles. He is a Leading innovator in genetics and synthetic biology. His innovations in genomics, computational biology, genetics and systems biology have been the basis for a number of companies. Dr. Church did Post-Doctoral Work at Harvard. Dr. Church holds a B.A. in Chemistry and Zoology from Duke University and a PhD in Biochemistry and Molecular Biology from Harvard in 1994.

Dr. Feng Zhang, Ph.D. has been Member of Scientific Advisory Board at PureTech Health plc since July 8, 2016. Dr. Zhang co-founded Editas Medicine Inc. in 2013. Dr. Zhang is an accomplished bioengineer focused on developing tools to better understand nervous system function and disease. He serves as W.M. Keck Career Development Professor with joint appointment in Biological Engineering and also Brain and Cognitive Sciences departments at the Massachusetts Institute of Technology (MIT). He served as a Joint Assistant Professor in the Departments of Brain and Cognitive Sciences and Biological Engineering at Massachusetts Institute of Technology. Dr. Zhang is also an investigator at the McGovern Institute for Brain Research at MIT and an assistant professor at MIT with a joint appointment in the departments of brain and cognitive sciences and biological engineering. As a student, he played a major role in the development of optogenetics, a technology that allows the brain's electrical activity to be controlled with light-sensitive proteins. He is working to extend this molecular engineering approach to other aspects of brain function, such as gene expression and to develop new approaches to understanding and treating brain diseases. He serves as serves Scientific Advisory Board Member at Editas Medicine Inc. Dr. Zhang serves as a Member of Scientific Advisory Board at Horizon Discovery Group plc and Horizon Discovery Limited. He successfully engineered the CRISPR-Cas9 system for genome editing in mammalian cells as published online January 3, 2013 in Sciences. He is also one of the 11 core members of the Broad Institute of MIT and Harvard and an Investigator at the McGovern Institute for Brain Research. Since joining MIT and the Broad Institute in January 2011, Dr. Zhang has pioneered the development of genome editing tools for use in eukaryotic cells including human cells from natural microbial CRISPR systems. He has been extremely active in publishing a range of articles on the optimal use and design of the technology. He has published compelling results indicating CRISPR/Cas9-mediated gene editing can be employed in high-throughput genome-wide screens. Dr. Zhang is a Searle Scholar and has received both a Director's Transformative Research Award and a Directors??? Pioneer Award from the National Institutes of Health. In 2012, he shared the UNC/Perl Prize for his role in the development of optogenetics. He is the 2014 recipient of the prestigious NSF Waterman award from the National Science Foundation for his work on the CRISPR-Cas9 system. In 2013 Popular Science named him one of its Brilliant Ten. He was named one of the Top 20 Researchers in 2014 by Nature Biotechnology, which considers the total impact of a scientist's body of published work. Dr. Zhang holds an A.B. in chemistry and physics from Harvard College and a Ph.D. in chemistry from Stanford University.

Vic Myer serves as the Chief Technology Officer of Editas Medicine. Vic started at Editas Medicine in April of 2015. Vic currently resides in Greater Boston Area.

Tim Hunt serves as the Senior Vice President, Corporate Affairs of Editas Medicine. Tim started at Editas Medicine in January of 2016. Tim currently resides in Greater Boston Area.

Rick Morgan serves as the Senior Vice President of Editas Medicine. Rick started at Editas Medicine in October of 2018. Rick currently resides in Greater Boston Area.

Kevin Dushney serves as the VP, Information Technology and Operations of Editas Medicine. Kevin started at Editas Medicine in May of 2017. Kevin currently resides in Greater Boston Area.

Jennifer Hunt serves as the Vice President, Clinical Operations of Editas Medicine. Jennifer started at Editas Medicine in March of 2018. Jennifer currently resides in Greater Boston Area.